IRIX - イリデックス （IRIDEX Corporation） イリデックスIRIXのチャート
IRIXの企業情報
| symbol | IRIx |
|---|---|
| 会社名 | IRIDEX Corp. （イリデックス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Biotechnology: Electromedical_Electrotherapeutic Apparatus |
| 業種 | 先端医療機器_テクノロジ― 医療関連（Health Care） |
| 概要 | 事業概要 イリデックス（IRIDEX Corporation）は眼科学における目の疾患の治療用の治療ベースのレーザーシステム、送達デバイス及び消耗器具のグローバルなプロバイダー。同社は主に眼科に集中する。同社の眼科治療商品は主に直販の方式で米国内に販売されて、100カ国以上における約70の独立系代理販売業者を介して国際的に販売される。同社の眼科治療商品は「IQ」と「OcuLight」レーザーシステム、消耗品、及びサービスと支援業務を含む。同社の「IQ」製品群は「IQ 532」、「IQ 577」と「IQ 810」のレーザー光凝固システムを含み、「OcuLight」商品は「OcuLight TX」、「OcuLight Symphony」（レーザー・デリバリー・システム）、「OcuLight SL」、「OcuLight SLx」、「OcuLight GL」及び「OcuLight GLx」のレーザー光凝固システムを含む。平成24年2月、同社はCutera Inc.に美容事業を譲渡した。 イリデックスは医療用レ―ザ―システムを提供する米国企業。眼疾患治療に使用されるレ―ザ―システム、送達デバイス及び消耗器具類などを開発、製造。糖尿病性網膜症、緑内障、加齢性黄斑変性症などの視力を脅かす眼の疾患を対象とする。販売代理店を通じて、世界的に製品を販売。本社はカリフォルニア州。 Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company's proprietary MicroPulse® technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex's current product line is used for the treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. |
| 本社所在地 | 1212 Terra Bella Avenue Mountain View CA 94043-1824 USA |
| 代表者氏名 | William M. Moore ウィリアム・M・ムーア |
| 代表者役職名 | Chairman of the Board Interim President and Chief Executive Officer |
| 電話番号 | +1 650-940-4700 |
| 設立年月日 | 32540 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 1996年 |
| 従業員数 | 154人 |
| url | www.iridex.com |
| nasdaq_url | https://www.nasdaq.com/symbol/irix |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -14.49200 |
| 終値（lastsale） | 5.925 |
| 時価総額（marketcap） | 69110260.575 |
| 時価総額 | 時価総額（百万ドル） 69.31863 |
| 売上高 | 売上高（百万ドル） 40.92100 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 53.27363 |
| 当期純利益 | 当期純利益（百万ドル） -15.13400 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 IRIDEX Corporation revenues decreased 3% to $19.8M. Net loss increased 49% to $6.9M. Revenues reflect United States segment decrease of 14% to $10M Asia/Pacific Rim segment decrease of 2% to $3.9M. Higher net loss reflects Selling/General/Admin. Expense increase of 26% to $8M (expense) Selling expenses increase of 25% to $4.4M (expense). |
IRIXのテクニカル分析
IRIXのニュース
Cosmetic Surgery Products Market Is Booming Worldwide with Strong Growth: Cynosure, Galderm, Iridex 2021/07/10 12:15:01 Tramways Monthly
A Latest intelligence report published by AMA Research with title Cosmetic Surgery Products Market Outlook to 2026.A detailed study accumulated to offer Latest insights about acute features of the Global Cosmetic Surgery Products market. This report provides a detailed overview of key factors in the Cosmetic Surgery Products Market and factors such as driver, restraint, []
Dermatology Lasers Market 2021-2028 | Size, Share, Growth, Trends, Competitive Landscape, Analysis, Revenue, Forecast Report 2021/07/07 11:19:00 Intrado Digital Media
Top Players Covered in the Dermatology Lasers Market Research Report are Alma Lasers, Lumenis, CYNOSURE, Miracle Laser & Skin Care, CANDELA CORPORATION, Focus Technology Co. Ltd., SINCOHEREN, Fotona, Alcon Vision LLC, IRIDEX Corporation and other key market players Top Players Covered in the Dermatology Lasers Market Research Report are Alma Lasers, Lumenis, CYNOSURE, Miracle Laser & Skin Care, CANDELA CORPORATION, Focus Technology Co. Ltd., SINCOHEREN, Fotona, Alcon Vision LLC, IRIDEX Corporation and other key market players
Looking Into Iridex''s Return On Capital Employed 2021/06/17 14:00:25 Benzinga
During Q1, Iridex ''s (NASDAQ: IRIX ) reported sales totaled $11.96 million. Despite a 513.67% in earnings, the company posted a loss of $1.84 million. In Q4, Iridex brought in $12.30 million in sales but lost $300.00 thousand in earnings. What Is ROCE? Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company''s ROCE. A higher ROCE is generally representative of successful growth of a company Full story available on Benzinga.com
IRIDEX Corporation (IRIX) CEO Dave Bruce on Q1 2021 Results - Earnings Call Transcript 2021/05/12 07:07:08 Seeking Alpha
Looking Into Iridex''s Return On Capital Employed 2021/06/17 14:00:25 Benzinga
During Q1, Iridex ''s (NASDAQ: IRIX ) reported sales totaled $11.96 million. Despite a 513.67% in earnings, the company posted a loss of $1.84 million. In Q4, Iridex brought in $12.30 million in sales but lost $300.00 thousand in earnings. What Is ROCE? Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company''s ROCE. A higher ROCE is generally representative of successful growth of a company Full story available on Benzinga.com
IRIDEX Corporation (IRIX) CEO Dave Bruce on Q1 2021 Results - Earnings Call Transcript 2021/05/12 07:07:08 Seeking Alpha
IRIDEX (NASDAQ:IRIX) Issues FY 2021 Earnings Guidance 2021/05/11 21:36:41 Transcript Daily
IRIDEX (NASDAQ:IRIX) updated its FY 2021 earnings guidance on Tuesday. The company provided EPS guidance of for the period. The company issued revenue guidance of $48 million-$51 million, compared to the consensus revenue estimate of $50.74 million. Several brokerages recently issued reports on IRIX. Zacks Investment Research upgraded IRIDEX from a sell rating to []
Iridex: Q1 Earnings Snapshot 2021/05/11 20:57:07 CityNews Vancouver
MOUNTAIN VIEW, Calif. (AP) _ Iridex Corp. (IRIX) on Tuesday reported a loss of $2 million in its first quarter. The Mountain View, California-based company said it had a loss of 14 cents per share. The medical laser company posted revenue of $12 million in the period. Iridex shares have nearly tripled since the beginning []